Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 November 2025 | Story Tshepo Tsotetsi | Photo Stephen Collett
Economist of the Year
Reatile Seekoei (centre), UFS’s 2025 Economist of the Year, with representatives from Sanlam and Santam.

University of the Free State (UFS) BCom Finance student Reatile Seekoei has again claimed the top prize in the UFS’s second annual Economist of the Year competition.

The event, hosted on 31 October 2025 by the Department of Economics and Finance in the Faculty of Economic and Management Sciences (EMS), brought together UFS students, academics, and parents at the Bloemfontein Campus to celebrate emerging talent in the field. The group was joined by sponsors from Sanlam and Santam.

The competition has quickly become a highlight on the academic calendar, offering students an opportunity to bridge classroom theory with real-world practice. It challenges them to apply their understanding of economic trends, policy analysis, and data interpretation to forecast future developments, helping them grow from students into confident, career-ready economists. The event also recognised the top-performing students in the department – from first-year level to master’s – in celebration of academic excellence.

 

Turning theory into practice

According to Prof Johan Coetzee, Head of the Department of Economics and Finance, the competition aims to give students a platform to apply what they learn in class to real-world scenarios. “The purpose of it is to expose students to macroeconomic indicators and to apply their forecasting skills,” he explained. “It forces students to read up on the news, to know what’s happening in the world around them, and to articulate their understanding clearly. In a world increasingly driven by AI, we need humans – we need economists – to set the narrative. This prepares them for the world of work.”

Prof Coetzee added that the judging focuses on both technical and communication skills, with 40% of the score based on forecasting accuracy and 60% on presentation and articulation. “Economists must not only understand the numbers, but also communicate what those numbers mean,” he said.

 

From conceptual thinker to confident economist

For Seekoei, winning the competition again was both a challenge and a statement of growth.

“I came into this competition for the second time with one goal: to defend my title,” he said. “To win again is thrilling because I had to deliver more than I did last year. It pushed me to grow from a more conceptualised economist into a mature one who can apply indicators and present economically well.”

His presentation impressed the judges with its structured approach. Seekoei built a framework that combined a baseline analysis of South Africa’s economy with an interpretation of leading indicators, inflation trends and monetary-policy direction. He credited his success to the guidance of his lecturers and his belief in self-discipline. “The key to my success is believing in myself,” he said. “It was me against myself. I had to deliver better than what I did last year, and that confidence made all the difference.”

The competition also saw outstanding performances from other finalists, including BCom student Malek Suhail as the first runner-up and BCom Law student Lunghile Rivombo as the second runner-up, both of whom impressed the judges and their peers with their analytical skill and innovative approach – a testament to the faculty’s interdisciplinary strength.

Prof Coetzee expressed gratitude to Sanlam and Santam for sponsoring the competition and helping to make the initiative possible. Their support, he noted, plays a vital role in nurturing future economists who are both analytically strong and socially aware.

As the department looks ahead to next year’s competition, Seekoei’s back-to-back wins set a new benchmark – one that will no doubt inspire his peers to challenge themselves, think critically, and forecast with both precision and passion.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept